Dopamine and serotonin transporters in patients with schizophrenia: An imaging study with [123I]β-CIT

Biological Psychiatry

Volumn 47, Issue 5, 2000, Pages 371-379

  Laruelle, Marc ^a   Abi Dargham, Anissa ^a,b,c   Van Dyck, Christopher ^a,b,c   Gil, Roberto ^a,b,c   D'Souza, D Cyril ^a,b,c   Krystal, John ^a,b,c   Seibyl, John ^a,b,c   Baldwin, Ronald ^a,b,c   Innis, Robert ^a,b,c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

123I CIT; Dopamine; Schizophrenia; Serotonin; SPECT; Transporters

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; SEROTONIN; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; BRAIN STEM; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGE FACTORS; BRAIN STEM; CARRIER PROTEINS; CASE-CONTROL STUDIES; COCAINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NEOSTRIATUM; NERVE TISSUE PROTEINS; SCHIZOPHRENIA; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0033952193     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00257-7     Document Type: Article

References (64)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R., Seibyl J., Bowers M., et al. Increased striatal dopamine transmission in schizophrenia Confirmation in a second cohort . Am J Psychiatry. 155:1998;761-767.
2. Abi-Dargham A., Laruelle M., Aghajanian G.K., Charney D., Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsych Clin Neurosci. 9:1997;1-17.
3. Allard P., Eriksson K., Ross S.B., Marcusson J.O. Unaltered [3H]GBR-12935 binding after chronic treatment with dopamine active drugs. Psychopharmacology. 102:1990;291-294.
4. Angrist B., van Kammen D.P. CNS stimulants as a tool in the study of schizophrenia. Trends Neurosci. 7:1984;388-390.
5. Ase A.R., Amdiss F., Hebert C., Huang N., van Gelder N.M., Reader T.A. Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin 1A receptors. J Neural Transm. 106:1999;75-105.
6. 123I]β-CIT) in nonhuman primates Pharmacokinetics, biodistribution and SPECT imaging coregistered with MRI . Nucl Med Biol. 20:1993;597-606.
7. 125I]RTI-55 A potent ligand for dopamine transporters . Eur J Pharmacol. 194:1991;133-134.
8. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., deBartolomeis A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations Evidence from a novel positron emission tomography method . Proc Natl Acad Sci U S A. 94:1997;2569-2574.
9. Burnet P.W., Eastwood S.L., Harrison P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 15:1996;442-455.
10. Burnet P.W.J., Eastwood S.L., Harrison P.J. [H-3]WAY-100635 for 5-HT1A receptor autoradiography in human brain A comparison with [H-3]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia . Neurochem Int. 30:1997;565-574.
11. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol. 20:1963;140-144.
12. 123I]3β-(4-Iodophenyl)tropan-2β-carboxylic acid methyl ester (RTI-55), a unique cocaine receptor ligand for imaging the dopamine and serotonin transporters in vivo. Med Chem Res. 1:1991;289-294.
13. Chang L.T. A method for attenuation correction in computed tomography. IEEE Trans Nucl Sci. NS-25:1987;638-643.
14. Chinaglia G., Alvarez F.J., Probst A., Palacios J.M. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy A quantitative autoradiographic study using [3H]mazindol . Neuroscience. 49:1992;317-327.
15. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 19:1976;481-483.
16. Czudek C., Reynolds G.P. [3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia. J Neural Transm. 77:1989;227-230.
17. Dao-Castellana M.H., Paillere-Martinot M.L., Hantraye P., Attar-Levy D., Remy P., Crouzel C., et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res. 23:1997;167-174.
18. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia A review and reconceptualization . Am J Psychiatry. 148:1991;1474-1486.
19. Dean B., Opeskin K., Pavey G., Naylor L., Hill C., Keks N. [3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J Neurochem. 64:1995;1197-1202.
20. Gurevich E.V., Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia A postmortem study . Biol Psychiatry. 42:1997;529-545.
21. Hagberg G., Gefvert O., Lindström L., Bergström M., Langström B. L-[beta-11C]DOPA utilization in schizophrenia. Neuroimage. 7:1998;A45.
22. Hantraye P., Brownell A.L., Elmaleh D., Spealman R.D., Wullner U., Brownell G.L., et al. Dopamine fiber detection by [11C]-CFT and PET in a primate model of parkinsonism. NeuroReport. 3:1992;265-268.
23. Hashimoto T., Nishino N., Nakai H., Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 48:1991;355-363.
24. Heinz A., Ragan P., Jones D.W., Hommer D., Williams W., Knable M.B., et al. Reduced central serotonin transporters in alcoholism. Am J Psychiatry. 155:1998;1544-1549.
25. Hietala J., Syvalahti E., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet. 346:1995;1130-1131.
26. Hirai M., Kitamura N., Hashimoto T., Nakai T., Mita T., Shirakawa O., et al. [3H]GBR-12935 binding sites in human striatal membranes Binding characteristics and changes in parkinsonians and schizophrenics . Jpn J Pharmacol. 47:1988;237-243.
27. Hollingshead AB (1975): Four factor index of social status. New Haven, CT: Working paper published by the author.
28. 123I]CIT. Eur J Pharmacol. 200:1991;369-370.
29. Innis R.B., Seibyl J.P., Scanley B.E., Laruelle M., Abi-Dargham A., Wallace E., et al. Single photon emission computed tomographic imaging demonstrates loss of striatal transporters in Parkinson's disease. Proc Natl Acad Sci. 90:1993;11965-11969.
30. Joyce J.N., Lexow N., Bird E., Winokur A. Organization of dopamine D1 and D2 receptors in human striatum Receptor autoradiographic studies in Huntington's disease and schizophrenia . Synapse. 2:1988;546-557.
31. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 8:1993;315-336.
32. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome scale (PANSS) for schizophrenia. Schiz Bull. 13:1987;261-276.
33. Knable M.B., Hyde T.M., Herman M.M., Carter J.M., Bigelow L., Kleinman J.E. Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol Psychiatry. 36:1994;827-835.
34. Laruelle M., Abi-Dargham A., Casanova M.F., Toti R., Weinberger D.R., Kleinman J.E. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia A postmortem study . Arch Gen Psychiatry. 50:1993;810-818.
35. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., Innis R. Increased dopamine transmission in schizophrenia Relationship to illness phases . Biol Psychiatry. 46:1999;56-72.
36. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., De Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects. Proc Natl Acad Sci U S A. 93:1996;9235-9240.
37. 123I]iodobenzofuran and single photon emission computerized tomography. Eur J Pharmacol. 263:1994;39-51.
38. 123I]β-CIT Pharmacological characterization of brain uptake in nonhuman primates . Synapse. 13:1993;295-309.
39. 2 receptors in healthy subjects. J Nucl Med. 35:1994;743-754.
40. 123I]β-CIT in vivo binding to dopamine transporters in healthy subjects. J Cereb Blood Flow Metab. 14:1994;982-994.
41. Lieberman J.A., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 91:1987;415-433.
42. Lieberman J.A., Kinon B.L., Loebel A.D. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schiz Bull. 16:1990;97-110.
43. Lieberman J.A., Mailman R.B., Duncan G., Sikich L., Chakos M., Nichols D.E., et al. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry. 44:1998;1099-1117.
44. Lieberman J.A., Sheitman B.B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia Deficits and dysfunction in neuronal regulation and plasticity . Neuropsychopharmacology. 17:1997;205-229.
45. Malison RT, Pelton G, Carpenter L, Sanacora G, Haroon E, Potenza M, et al (1997): Reduced midbrain serotonin transporter binding in depressed v healthy subjects as measured by [123I]b-CIT. Soc Neurosci Abstr 1220.
46. Malison R.T., Price L.H., Berman R., van Dyck C.H., Pelton G.H., Carpenter L., et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3-beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry. 44:1998;1090-1098.
47. Martin P., Waters N., Schmidt C.J., Carlsson A., Carlsson M.L. Rodent data and general hypothesis Antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone . J Neural Transm. 105:1998;365-396.
48. Mintun M.A., Raichle M.E., Kilbourn M.R., Wooten G.F., Welch M.J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 15:1984;217-227.
49. Naylor L., Dean B., Opeskin K., Pavey G., Hill C., Keks N., et al. Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine. J Neural Transm Gen Sect. 103:1996;749-757.
50. 123I]2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT) High affinity SPECT radiotracer of monoamine reuptake sites in brain . J Med Chem. 34:1991;3144-3146.
51. O'Donnell P., Grace A.A. Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. Schizophr Bull. 24:1998;267-283.
52. Pearce R.K., Seeman P., Jellinger K., Tourtellotte W.W. Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia. Eur Neurol. 30:(Suppl 1):1990;9-14.
53. Pirker W., Asenbaum S., Kasper S., Walter H., Angelberger P., Koch G. Beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect. 100:1995;247-256.
54. Reader T.A., Ase A.R., Huang N., Hebert C., van Gelder N.M. Neuroleptics and dopamine transporters. Neurochem Res. 23:1998;73-80.
55. Reith J., Benkelfat C., Sherwin A., Yasuhara Y., Kuwabara H., Andermann F., et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A. 91:1994;11651-11654.
56. Rivest R., Falardeau P., Di Paolo T. Brain dopamine transporter Gender differences and effect of chronic haloperidol . Brain Res. 692:1995;269-272.
57. Seeman P., Lee T. Antipsychotic drugs Direct correlation between clinical potency and presynaptic action on dopamine neurons . Science. 188:1975;1217-1219.
58. Simpson M.D., Lubman D.I., Slater P., Deakin J.F. Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT(1A) receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiatry. 39:1996;919-928.
59. Soares J.C., Innis R.B. Neurochemical brain imaging investigations of schizophrenia. Biol Psychiatry. 46:1999;600-615.
60. Sumiyoshi T., Stockmeier C.A., Overholser J.C., Dilley G.E., Meltzer H.Y. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 708:1996;209-214.
61. Van Dyck C.H., Seibyl J.P., Malisson R.T., Laruelle M., Wallace E., Zoghbi S.S., et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med. 36:1995;1175-1181.
62. Volkow N.D., Fowler J.S., Wang G.J., Logan J., Schlyer D., MacGregor R., et al. Decreased dopamine transporters with age in health human subjects. Ann Neurol. 36:1994;237-239.
63. Weinberger D.R. Implications of the normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 44:1987;660-669.
64. Zelnik N., Angel I., Paul S.M., Kleinman J.E. Decreased density of human striatal dopamine uptake sites with age. Eur J Pharmacol. 126:1986;287-295.